Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines

Jemal, 2010, Cancer statistics, 2010, Cancer J Clin, 60, 277, 10.3322/caac.20073

Mok, 2009, Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma, N Engl J Med, 361, 947, 10.1056/NEJMoa0810699

Maemondo, 2010, Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR, N Engl J Med, 362, 2380, 10.1056/NEJMoa0909530

Masago, 2011, Clinicopathologic factors affecting the progression-free survival of patients with advanced non-small-cell lung cancer after gefitinib therapy, Clin Lung Cancer, 12, 56, 10.3816/CLC.2011.n.008

Pao, 2005, KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib, PLoS Med, 2, e17, 10.1371/journal.pmed.0020017

Gazdar, 2009, Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors, Oncogene, 28, S24, 10.1038/onc.2009.198

Rodenhuis, 1988, Incidence and possible clinical significance of K-ras oncogene activation in adenocarcinoma of the human lung, Cancer Res, 48, 5738

Mitsudomi, 2005, Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence, J Clin Oncol, 23, 2513, 10.1200/JCO.2005.00.992

Kosaka, 2006, Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib, Clin Cancer Res, 12, 5764, 10.1158/1078-0432.CCR-06-0714

Toi, 2001, Vascular endothelial growth factor:its prognostic, predictive, and therapeutic implications, Lancet Oncol, 2, 667, 10.1016/S1470-2045(01)00556-3

Alvarez, 2006, Biology of platelet-derived growth factor and its involvement in disease, Mayo Clinic Proceedings, 81, 1241, 10.4065/81.9.1241

Ferrara, 2003, The biology of VEGF and its receptors, Nat Med, 9, 669, 10.1038/nm0603-669

Wu, 2008, Comprehensive dissection of PDGF-PDGFR signaling pathways in PDGFR genetically defined cells, PLoS One, 3, e3794, 10.1371/journal.pone.0003794

Erber, 2004, Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms, FASEB J, 18, 338, 10.1096/fj.03-0271fje

Shikada, 2005, Platelet-derived growth factor-AA is an essential and autocrine regulator of vascular endothelial growth factor expression in non-small cell lung carcinomas, Cancer Res, 65, 7241, 10.1158/0008-5472.CAN-04-4171

Donnem, 2010, Co-expression of PDGF-B and VEGFR-3 strongly correlates with lymph node metastasis and poor survival in non-small-cell lung cancer, Ann Oncol, 21, 223, 10.1093/annonc/mdp296

Linardou, 2008, Assessment of somatic k-Ras mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small cell lung cancer and colorectal cancer, Lancet Oncol, 9, 962, 10.1016/S1470-2045(08)70206-7

Rodenhuis, 1987, Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung, N Engl J Med, 317, 929, 10.1056/NEJM198710083171504

Lopez-Chavez, 2009, The role of KRAS mutations in resistance to EGFR inhibition in the treatment of cancer, Curr Opin Investig Drugs, 10, 1305

Wilhelm, 2004, BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Res, 64, 7099, 10.1158/0008-5472.CAN-04-1443

Dal Lago, 2008, Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors, Oncologist, 13, 845, 10.1634/theoncologist.2007-0233

Blumenschein, 2009, Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer, J Clin Oncol, 27, 4274, 10.1200/JCO.2009.22.0541

Dy, 2010, A front-line window of opportunity phase 2 study of sorafenib in patients with advanced nonsmall cell lung cancer: North Central Cancer Treatment Group Study N0326, Cancer, 116, 5686, 10.1002/cncr.25448

Carter, 2007, Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma, Cancer Chemother Pharmacol, 59, 183, 10.1007/s00280-006-0257-y

Scagliotti, 2010, Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small cell lung cancer, J Clin Oncol, 28, 1835, 10.1200/JCO.2009.26.1321

Paz-Ares, 2012, Phase III, randomized, double-blind, placebo-controlled trial of gemcitabine/cisplatin alone or with sorafenib for the first-line treatment of advanced, nonsquamous non-small-cell lung cancer, J Clin Oncol, 30, 3084, 10.1200/JCO.2011.39.7646

Plastaras, 2007, Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation, Cancer Res, 67, 9443, 10.1158/0008-5472.CAN-07-1473

Takezawa, 2009, Sorafenib inhibits non-small cell lung cancer cell growth by targeting B-RAF in KRAS wild-type cells and C-RAF in KRAS mutant cells, Cancer Res, 69, 6515, 10.1158/0008-5472.CAN-09-1076

Mahaffey, 2007, Schedule-dependent apoptosis in K-ras mutant non-small-cell lung cancer cell lines treated with docetaxel and erlotinib: rationale for pharmacodynamic separation, Clin Lung Cancer, 8, 548, 10.3816/CLC.2007.n.041

Cheng, 2011, In vitro sequence-dependent synergism between paclitaxel and gefitinib in human lung cancer cell lines, Cancer Chemother Pharmacol, 67, 637, 10.1007/s00280-010-1347-4

Dougherty, 2010, Gemcitabine and other new cytotoxic drugs: will any find their way into primary therapy?, Curr Hematol Malig Rep, 5, 148, 10.1007/s11899-010-0054-x

Mosmann, 1983, Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays, J Immunol Methods, 65, 55, 10.1016/0022-1759(83)90303-4

Chou, 1984, Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors, Adv Enzyme Regul, 22, 27, 10.1016/0065-2571(84)90007-4

Strumberg, 2007, Safety, pharmacokinetics, and preliminary antitumor activity of sorafenib: a review of four phase I trials in patients with advanced refractory solid tumors, Oncologist, 12, 426, 10.1634/theoncologist.12-4-426

Rajeswaran, 2008, Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of meta-static non-small cell lung carcinoma: a systematic review of randomized controlled trials, Lung Cancer, 59, 1, 10.1016/j.lungcan.2007.07.012

Maemondo, 2012, Timing the change of chemotherapy for non-small cell lung cancer, Gan To Kagaku Ryoho, 39, 1316

Ayoola, 2012, Primary and acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer: an update, Cancer Invest, 30, 433, 10.3109/07357907.2012.666691

Petrelli, 2008, From single- to multi-target drugs in cancer therapy: when aspecificity becomes an advantage, Curr Med Chem, 15, 422, 10.2174/092986708783503212

Pasqualetti, 2011, Synergistic cytotoxicity, inhibition of signal transduction pathways and pharmacogenetics of sorafenib and gemcitabine in human NSCLC cell lines, Lung Cancer, 74, 197, 10.1016/j.lungcan.2011.03.003

Zhang, 2012, Synergistic antitumor efficacy of sequentially combined paclitaxel with sorafenib in vitro and in vivo NSCLC models harboring KRAS or BRAF mutations, Cancer Lett, 322, 213, 10.1016/j.canlet.2012.03.015

Ulivi, 2010, In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells, Curr Cancer Drug Targets, 10, 600, 10.2174/156800910791859489

Torres, 1998, Mechanisms of taxol-induced cell death are concentration dependent, Cancer Res, 58, 3620

Li, 2012, Activation of PI3K/AKT and MAPK pathway through a PDGFRβ-dependent feedback loop is involved in rapamycin resistance in hepatocellular carcinoma, PLoS One, 7, e33379, 10.1371/journal.pone.0033379